The United States Food & Drugs Administration (FDA) has officially approved GW Pharmaceuticals’ (NASDAQ: GWPH) Cannabidiol (CBD) derived medication called Epidiolex. The newly approved drug is a oral solution that is used for the reduction of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
The new CBD derived pharmaceutical will be available to patients through a medical doctors perception for individuals 2 years old or older that suffer from these life crippling diseases.
The approval process has take place over the past few years. The FDA has conducted a series of randomized clinical trials with hundreds of patients suffering from Lennox-Gastaut syndrome and Dravet syndrome. The results found Epidiolex, in conjunction with other medications, to be an efficient solution in the reduction of seizures associated with these conditions.
This announcement should be observed as a huge step forward in the public’s perception of the cannabinoid known as CBD and officially verifies that the compound contains medicinal benefits. Cannabidiol is non-psychoactive and can be extracted from the cannabis and industrial hemp plants but, has yet to be distinguished away from its schedule-1 drug classification by the FDA.
“The difficult-to-control seizures that patients with Dravet syndrome and Lennox-Gastaut syndrome experience have a profound impact on these patients’ quality of life,” said Billy Dunn, M.D., director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research. “In addition to another important treatment option for Lennox-Gastaut patients, this first-ever approval of a drug specifically for Dravet patients will provide a significant and needed improvement in the therapeutic approach to caring for people with this condition.”
You may be interested
Columbia Care Receives Licenses from Maltese GovernmentEditor - November 15, 2018
Columbia Care LLC. has announced this morning that the company has gain approval from Malta Enterprises, the regulatory economic development agency in the country, to receive licenses…
Tilray Announces Impressive 2018 Q3 FinancialsEditor - November 14, 2018
Wholly-owned subsidiary of Privateer Holdings, Inc., Tilray (NASDAQ: TLRY), has announced the company’s third quarter financial statements for 2018 this morning. Earlier this year, Tilray debuted its…
Valens Signs Cannabidnoid Extraction and R&D Agreement with Harvest OneEditor - November 14, 2018
Valen GroWorks Corp. (CSE: VGW) (OTC-QB: MYMSF) has announced this morning that the company has entered into an agreement with Harvest One (TSXV:HVT) to provide services in…